NASDAQ · REGN

Regeneron Pharmaceuticals Inc.

$686.89 +$30.88 (+4.71%) 1D Market open
Session Pulse Regular session 1 mentions on Fri · 0 bullish / 1 bearish tags No new SEC filings since Mon close its sector ranked 5/11 this week Full pulse →
Charting by TradingView

Key Metrics

$68.78B
Market cap
15.55×
P/E · TTM
$14.92B
Revenue · TTM
$4.42B
Net income
EPS · TTM $39.78
Dividend yield 0.5%
Free cash flow $4.11B
Beta · 1Y 0.41
EBITDA · TTM $5.70B
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 1
    From its Feb 13 high, the share price fell 25%.

    Peak close $803.17 on Feb 13; trough close $600.66 on Jun 1. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -25%
  • May 18
    The stock moved -9.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 18

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$68.78B
Enterprise value$52.22B
Shares outstanding104.8M
52-wk range$541.00 – $821.11
Avg volume · 20D767.0K
Net cash $16.55B
Book value / share$282.59
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Regeneron Pharmaceuticals Inc.
IPO dateApr 2, 1991
Employees15410

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E15.55
P/S4.61
P/FCF16.72
EV/EBITDA9.17
EV/Sales3.50
Graham №$502.91

Profitability

Gross —
Operating 34.6%
Net 29.6%
FCF 27.6%
ROE / ROIC 14.6% · 17.9%

Financial Health

Current ratio3.57
Quick ratio2.96
Debt / equity0.06
Debt / EBITDA 0.35Low leverage
Net cash $16.55B
Working capital$13.10B

Cash Flow · TTM

Operating CF $5.01B
Capex −$899.70M
Free cash flow $4.11B
Buybacks $3.19B
Dividends paid $374.30M
Shareholder yield 5.2%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

6.8
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$502.91 vs $667.17
Trades 1.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings